MannKind (MNKD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Election of nine director nominees to serve for the ensuing year and until successors are elected.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Provision to transact other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Nine individuals nominated for election to the board, including James S. Shannon, Michael E. Castagna, and others.
Executive compensation and say-on-pay
Advisory vote scheduled to approve the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MannKind
- Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKD
Q4 20258 Jul 2026 - Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKD
Q1 20258 Jul 2026 - Diversified growth, new launches, and pipeline advances set the stage for accelerated revenue and margin expansion.MNKD
Leerink Global Healthcare Conference 202630 Jun 2026 - Pediatric Afrezza approval and FUROSCIX auto-injector drive growth amid strong pipeline progress.MNKD
Jefferies Global Healthcare Conference 20263 Jun 2026 - FDA approved Afrezza for children 6+, enabling the first inhaled mealtime insulin for pediatrics.MNKD
FDA announcement29 May 2026 - Directors elected, compensation and auditor ratified, with strong growth and pipeline updates shared.MNKD
AGM 202620 May 2026 - Q1 2026 revenue up 15% to $90.2M, but higher expenses led to a $16.6M net loss.MNKD
Q1 20267 May 2026 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.MNKD
Proxy filing7 Apr 2026 - Double-digit growth and two major launches expected as diversification and innovation accelerate.MNKD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026